Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats

Overview

Journal Biomol Ther (Seoul)

Specialty Pharmacology

Date 2020 Mar 27

PMID 32209733

Citations 11

Authors

Eun Hye Gwak

Hee Young Yoo

So Hee Kim

Affiliations

Soon will be listed here.

Abstract

Tofacitinib, a Janus kinase inhibitor, was developed for the treatment of rheumatoid arthritis. Recently, it has been associated with an increased change in arthritis development in patients with diabetes. Herein, we evaluated the pharmacokinetics of tofacitinib after intravenous (10 mg/kg) and oral (20 mg/kg) administration to rats with streptozotocin-induced diabetes mellitus and control rats. Following intravenous administration of tofacitinib to rats with streptozotocin-induced diabetes mellitus, area under the plasma concentration-time curve from time zero to infinity of tofacitinib was significantly smaller (33.6%) than that of control rats. This might be due to the faster hepatic intrinsic clearance (112%) caused by an increase in the hepatic cytochrome P450 (CYP) 3A1(23) and the faster hepatic blood flow rate in rats with streptozotocin-induced diabetes mellitus than in control rats. Following oral administration, area under the plasma concentration-time curve from time zero to infinity of tofacitinib was also significantly smaller (55.5%) in rats with streptozotocin-induced diabetes mellitus than that in control rats. This might be due to decreased absorption caused by the higher expression of P-glycoprotein and the faster intestinal metabolism caused by the higher expression of intestinal CYP3A1(23), which resulted in the decreased bioavailability of tofacitinib (33.0%) in rats with streptozotocin-induced diabetes mellitus. In summary, our findings indicate that diabetes mellitus affects the absorption and metabolism of tofacitinib, causing faster metabolism and decreased intestinal absorption in rats with streptozotocin-induced diabetes mellitus.

Citing Articles

The Impact of Baohuoside I on the Metabolism of Tofacitinib in Rats.

Shi Y, Lu Z, Song W, Wang Y, Zhou Q, Geng P Drug Des Devel Ther. 2024; 18:931-939.

PMID: 38560524 PMC: 10980839. DOI: 10.2147/DDDT.S436549.

Expression of Enzyme in Human Liver Tissue of HIV and HCV Patients.

Obradovic B, Roberts O, Owen A, Milosevic I, Milic N, Ranin J Medicina (Kaunas). 2023; 59(7).

PMID: 37512019 PMC: 10385124. DOI: 10.3390/medicina59071207.

Pharmacokinetic assessment of cefpodoxime proxetil in diabetic rats.

Mittal G, Jakhar P, Patel A, Bhagwat D J Diabetes Metab Disord. 2023; 22(1):385-392.

PMID: 37255782 PMC: 10225406. DOI: 10.1007/s40200-022-01156-3.

Drug-induced liver injury due to tofacitinib: a case report.

Mardani M, Mohammadshahi J, Abolghasemi S, Teimourpour R J Med Case Rep. 2023; 17(1):97.

PMID: 36932434 PMC: 10024406. DOI: 10.1186/s13256-023-03821-4.

Effects of Isosakuranetin on Pharmacokinetic Changes of Tofacitinib in Rats with -Dimethylnitrosamine-Induced Liver Cirrhosis.

Bae S, Choi H, Park S, Chang S, Kim H, Kim S Pharmaceutics. 2022; 14(12).

PMID: 36559177 PMC: 9783783. DOI: 10.3390/pharmaceutics14122684.

References

Kim S, Lee J, Lee M . Stability, blood partition and plasma protein binding of ipriflavone, an isoflavone derivative. Biopharm Drug Dispos. 2000; 20(7):355-60. DOI: 10.1002/(sici)1099-081x(199910)20:7<355::aid-bdd197>3.0.co;2-x. View

Fukuda T, Naganuma M, Kanai T . Current new challenges in the management of ulcerative colitis. Intest Res. 2019; 17(1):36-44. PMC: 6361009. DOI: 10.5217/ir.2018.00126. View

Papp K, Menter M, Abe M, Elewski B, Feldman S, Gottlieb A . Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015; 173(4):949-61. DOI: 10.1111/bjd.14018. View

Tahir H . Therapies in ankylosing spondylitis-from clinical trials to clinical practice. Rheumatology (Oxford). 2018; 57(suppl_6):vi23-vi28. PMC: 6238222. DOI: 10.1093/rheumatology/key152. View

Nadai M, Yoshizumi H, Kuzuya T, Hasegawa T, Johno I, Kitazawa S . Effect of diabetes on disposition and renal handling of cefazolin in rats. Drug Metab Dispos. 1990; 18(5):565-70. View

Shin W, Lee M, Lee M, Kim N . Factors influencing the protein binding of vancomycin. Biopharm Drug Dispos. 1991; 12(9):637-46. DOI: 10.1002/bdd.2510120902. View

Duggleby R . Analysis of enzyme progress curves by nonlinear regression. Methods Enzymol. 1995; 249:61-90. DOI: 10.1016/0076-6879(95)49031-0. View

Coombs J, Bloom B, Breedveld F, Fletcher M, Gruben D, Kremer J . Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2009; 69(2):413-6. DOI: 10.1136/ard.2009.108159. View

LaBranche T, Jesson M, Radi Z, Storer C, Guzova J, Bonar S . JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum. 2012; 64(11):3531-42. DOI: 10.1002/art.34649. View

10.

Antonelli E, Villanacci V, Bassotti G . Novel oral-targeted therapies for mucosal healing in ulcerative colitis. World J Gastroenterol. 2019; 24(47):5322-5330. PMC: 6305528. DOI: 10.3748/wjg.v24.i47.5322. View

11.

Kim S, Choi Y, Lee M . Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition. J Pharmacokinet Biopharm. 1993; 21(1):1-17. DOI: 10.1007/BF01061772. View

12.

Carnovale C, Marinelli R, RODRIGUEZ GARAY E . Bile flow decrease and altered bile composition in streptozotocin-treated rats. Biochem Pharmacol. 1986; 35(15):2625-8. DOI: 10.1016/0006-2952(86)90063-8. View

13.

Oie S, Guentert T . Stability of heparin and other fractions of glycosaminoglycan sulfates in human digestive juices. J Pharm Sci. 1982; 71(1):127-8. DOI: 10.1002/jps.2600710136. View

14.

Choi Y, Lee D, Lee I, Lee M . Changes in metformin pharmacokinetics after intravenous and oral administration to rats with short-term and long-term diabetes induced by streptozotocin. J Pharm Sci. 2008; 97(12):5363-75. DOI: 10.1002/jps.21349. View

15.

Hussar D . 2013 new drug update: what do new approvals hold for the elderly?. Consult Pharm. 2014; 29(4):224-38. DOI: 10.4140/TCP.n.2014.224. View

16.

Bae S, Park J, Choi H, Kim H, Kim S . Imidazole Antifungal Drugs Inhibit the Cell Proliferation and Invasion of Human Breast Cancer Cells. Biomol Ther (Seoul). 2018; 26(5):494-502. PMC: 6131009. DOI: 10.4062/biomolther.2018.042. View

17.

Chiou W . Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level--time curve. J Pharmacokinet Biopharm. 1978; 6(6):539-46. DOI: 10.1007/BF01062108. View

18.

Dowty M, Lin J, Ryder T, Wang W, Walker G, Vaz A . The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014; 42(4):759-73. DOI: 10.1124/dmd.113.054940. View

19.

Lee D, Chung H, Choi Y, Lee U, Kim S, Lee I . Pharmacokinetics of ipriflavone and its two metabolites, M1 and M5, after the intravenous and oral administration of ipriflavone to rat model of diabetes mellitus induced by streptozotocin. Eur J Pharm Sci. 2009; 38(5):465-71. DOI: 10.1016/j.ejps.2009.09.008. View

20.

Claxton L, Taylor M, Soonasra A, Bourret J, Gerber R . An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective. J Manag Care Spec Pharm. 2018; 24(10):1010-1017. PMC: 10397979. DOI: 10.18553/jmcp.2018.17220. View